NASDAQ : AUPH
Aurinia Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 16.65 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.22B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.23B |
| Enterprise Value | 1.80B |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 134.00M |
| Shares Outstanding | 134.00M |
| Shares Change (YoY) | -4.00% |
| Shares Change (QoQ) | +1.23% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 64.30% |
| Float | 129.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 7.22 |
| Forward PE | 20.16 |
| PS Ratio | 6.93 |
| Forward PS | 6.30 |
| PB Ratio | 3.39 |
| P/TBV Ratio | 3.41 |
| P/FCF Ratio | 12.60 |
| P/OCF Ratio | 12.59 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 5.74 |
| EV / Sales | 5.60 |
| EV / EBITDA | 9.73 |
| EV / EBIT | 10.86 |
| EV / FCF | 10.19 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.12 |
| Quick Ratio | 5.57 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.32 |
| Debt / FCF | 0.33 |
| Interest Coverage | 42.87 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 61.42% |
| Return on Assets (ROA) | 15.34% |
| Return on Invested Capital (ROIC) | 71.33% |
| Return on Capital Employed (ROCE) | 22.76% |
| Weighted Average Cost of Capital (WACC) | 12.91% |
| Revenue Per Employee | $2.51M |
| Profits Per Employee | $2.46M |
| Employee Count | 128 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 1.77 |
Taxes
| Measure | Value |
|---|
| Income Tax | -147.15M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.61 |
| 52-Week Price Change | +36.25% |
| 50-Day Moving Average | 16.49 |
| 200-Day Moving Average | 15.65 |
| Relative Strength Index (RSI) | 49.48 |
| Average Volume (20 Days) | 781,757 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.78M |
| Short Previous Month | 7.92M |
| Short % of Shares Out | 5.81% |
| Short % of Float | 6.02% |
| Short Ratio (days to cover) | 8.95 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 321.74M |
| Gross Profit | 243.55M |
| Operating Income | 166.07M |
| Pretax Income | 167.12M |
| Net Income | 314.27M |
| EBITDA | 185.42M |
| EBIT | 166.07M |
| Earnings Per Share (EPS) | $2.31 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 486.53M |
| Total Debt | 58.66M |
| Net Cash | 427.86M |
| Net Cash Per Share | $3.19 |
| Equity (Book Value) | 657.52M |
| Book Value Per Share | 4.91 |
| Working Capital | 491.88M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 177.16M |
| Capital Expenditures | -135,000 |
| Depreciation & Amortization | 19.36M |
| Net Borrowing | -14.39M |
| Free Cash Flow | 177.03M |
| FCF Per Share | $1.32 |
Margins
| Measure | Value |
|---|
| Gross Margin | 75.70% |
| Operating Margin | 51.61% |
| Pretax Margin | 51.94% |
| Profit Margin | 97.68% |
| EBITDA Margin | 57.63% |
| EBIT Margin | 51.61% |
| FCF Margin | 55.02% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 4.00% |
| Shareholder Yield | 4.00% |
| Earnings Yield | 13.85% |
| FCF Yield | 7.93% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $18.29 |
| Price Target Difference | 9.85% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 16.51% |
| EPS Growth Forecast (3Y) | -19.41% |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 23, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 7.95 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |